Search clinical trials for: MORAb-009 (Amatuximab)

Total 4199 results

Morphotek

Completed

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Pancreatic Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Amatuximab for High Mesothelin Cancers

Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Mesothelioma | Carcinoma, Pancreatic Ductal

United States
Eisai Co., Ltd.

Completed

A Study of MORAb-009 in Patients With Solid Tumor

Cancer | Mesothelin-positive

Japan
Morphotek

Completed

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma (Amatuximab)

Malignant Pleural Mesothelioma

United States, Canada, Germany, Spain, Netherlands
Morphotek

Completed

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Mesothelioma

United States
Eisai Co., Ltd.

Completed

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

Solid Tumor

Japan
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Morphotek

Terminated

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Metastatic Colorectal Cancer | Colorectal Cancer

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
Morphotek

Completed

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Epithelial Ovarian Cancer

United States
Morphotek

Withdrawn

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Resectable, Non-functioning Pituitary Adenoma

United States
Eisai Co., Ltd.

Completed

A Study of MORAb-003 in Patients With Solid Tumor

Neoplasms | Solid Tumor

Japan
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Morphotek

Terminated

An Open Label Extension Study of the Efficacy of MORAb-003

Epithelial Ovarian Cancer

United States, Germany
Morphotek

Completed

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Germany
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Eisai Inc.

Completed

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Metastatic Melanoma

United States, Australia, United Kingdom, Germany
Morphotek

Completed

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Epithelial Ovarian Cancer

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
Morphotek

Completed

A Study of of MORAb-004 in Subjects With Solid Tumors

Solid Tumor

United States
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Isatuximab in Type I Cryoglobulinemia (ICE)

Multiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Cryoglobulinemic Vasculitis
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating EKB-569 in Advanced Colorectal Cancer

Colorectal Neoplasms | Rectal Neoplasms | Colonic Neoplasms
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
Bonti, Inc.

Completed

Study of EB-001 in Facial Scar Reduction

Mohs Surgery

United States
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
Causeway Therapeutics

Recruiting

Efficacy and Safety of TenoMiR in Lateral Epicondylitis

Tennis Elbow

United Kingdom
Alexza Pharmaceuticals, Inc.

Completed

Staccato Apomorphine Single and Multi Dose PK

Parkinson Disease

Netherlands
Thomas Martin, MD

Withdrawn

Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
Morphotek

Completed

An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer

Pancreatic Cancer

United States, Canada, Spain, Belgium, Germany
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Morphotek
SCRI Development Innovations, LLC

Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Adenocarcinoma | Breast Cancer | Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Pancreatic Cancer

United States
Divaya Bhutani
Genzyme, a Sanofi Company

Recruiting

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Lymphoma | Multiple Myeloma | Non-Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

United States
Firas El Chaer, MD

Recruiting

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

Hematologic Malignancy | Platelet Refractoriness

United States
Alexza Pharmaceuticals, Inc.

Completed

Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

Parkinson's Disease

Netherlands
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Berlin Cures GmbH

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

Healthy Volunteers

Germany
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
Memorial Sloan Kettering Cancer Center
Sanofi

Recruiting

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Blood Cancer | Refractory Immune Cytopenias

United States
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Morphotek

Terminated

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (FAR-122)

Ovarian Cancer

Canada, United States, Netherlands, Spain, Belgium, Australia
Columbia University
Genzyme, a Sanofi Company

Recruiting

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Monoclonal Gammopathy

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell Transplantation (ErythroSIM)

Immunological Pure Red Cell Aplasia
VA Office of Research and Development

Completed

Pilot Study Testing a Web-Based Moral Elevation Intervention for Veterans With PTSD and Moral Injury

Posttraumatic Stress Disorder | Moral Injury

United States
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States

Search clinical trials for: MORAb-009 (Amatuximab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations